Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vericel Corproation (VCEL)

Vericel Corproation (VCEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,133,908
  • Shares Outstanding, K 45,429
  • Annual Sales, $ 117,850 K
  • Annual Income, $ -9,670 K
  • 60-Month Beta 3.06
  • Price/Sales 8.93
  • Price/Cash Flow 115.46
  • Price/Book 9.89
Trade VCEL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.23
  • Number of Estimates 4
  • High Estimate 0.28
  • Low Estimate 0.19
  • Prior Year 0.20
  • Growth Rate Est. (year over year) +15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.09 +39.30%
on 10/30/20
26.22 -3.89%
on 11/16/20
+4.87 (+23.95%)
since 10/27/20
3-Month
14.84 +69.81%
on 09/04/20
26.22 -3.89%
on 11/16/20
+8.59 (+51.72%)
since 08/27/20
52-Week
6.78 +271.68%
on 03/19/20
26.22 -3.89%
on 11/16/20
+6.40 (+34.04%)
since 11/27/19

Most Recent Stories

More News
Vericel Reports Record Third Quarter Revenues and Net Income

Total Net Revenues of $32.3 Million and Net Income of $3.6 Million

VCEL : 25.20 (+0.96%)
Stock Investors: What's the Next Hot Industry?

Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.

XLK : 122.66 (+0.53%)
QQQ : 299.01 (+0.92%)
EXAS : 118.19 (+2.00%)
VCEL : 25.20 (+0.96%)
INMD : 43.72 (+0.30%)
Vericel Corp, Nikola Corp, Lowe's, Dollar General and Best Buy highlighted as Zacks Bull and Bear of the Day

Vericel Corp, Nikola Corp, Lowe's, Dollar General and Best Buy highlighted as Zacks Bull and Bear of the Day

BBY : 112.63 (-1.12%)
DG : 218.01 (+0.47%)
LOW : 154.67 (-0.14%)
VCEL : 25.20 (+0.96%)
NKLA : 27.93 (-7.64%)
Bull of the Day: Vericel (VCEL)

Bull of the Day: Vericel (VCEL)

VCEL : 25.20 (+0.96%)
Fresh Start for November as Dow, S&P Each Gain Over 1%

Fresh Start for November as Dow, S&P Each Gain Over 1%

FIZZ : 94.90 (-0.17%)
WHR : 200.96 (+0.42%)
DKS : 59.49 (-0.95%)
AAP : 149.93 (+0.35%)
VCEL : 25.20 (+0.96%)
QQQJ : 28.92 (+1.08%)
FVC : 29.76 (+0.82%)
PRF : 130.13 (-0.08%)
SEE : 44.53 (-1.53%)
KBR : 28.26 (-0.07%)
HBI : 14.43 (-0.48%)
BBY : 112.63 (-1.12%)
EAT : 52.42 (+0.27%)
BG : 60.84 (-1.60%)
TGT : 179.77 (-0.03%)
APHA : 7.73 (+10.27%)
CGC : 29.00 (+7.93%)
STZ : 204.81 (+0.05%)
Vericel to Present at Upcoming Investor Conferences

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations at the following upcoming investor conferences.

VCEL : 25.20 (+0.96%)
Vericel Corp (VCEL) Sees Hammer Chart Pattern: Time to Buy?

Vericel Corp (VCEL) has been struggling lately, but the selling pressure may be coming to an end soon.

VCEL : 25.20 (+0.96%)
Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance

Alkermes (ALKS) beats earnings and sales estimates in the third quarter of 2020. The company also raises 2020 guidance.

JNJ : 144.00 (+0.22%)
ALKS : 18.50 (+0.38%)
EBS : 82.83 (+3.01%)
VCEL : 25.20 (+0.96%)
Alexion (ALXN) Beats on Q3 Earnings & Sales, Ups '20 Guidance

Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.

ALXN : 123.83 (+0.73%)
EBS : 82.83 (+3.01%)
VCEL : 25.20 (+0.96%)
CSTL : 44.47 (+2.00%)
Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.

RDY : 65.37 (+1.62%)
EBS : 82.83 (+3.01%)
VCEL : 25.20 (+0.96%)
CSTL : 44.47 (+2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

2nd Resistance Point 25.99
1st Resistance Point 25.60
Last Price 25.20
1st Support Level 24.89
2nd Support Level 24.57

See More

52-Week High 26.22
Last Price 25.20
Fibonacci 61.8% 18.79
Fibonacci 50% 16.50
Fibonacci 38.2% 14.21
52-Week Low 6.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar